ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2020

Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease

Anna Nagel1, Bhuwan Khatri1, Marcin Radziszewski1, Mandi Wiley1, Anna Stolarczyk1, Michelle Joachims1, Kandice Tessneer1, Astrid Rasmussen1, Professor Simon Bowman2, Lida Radfar3, Roald Omdal4, Marie Wahren-Herlenius5, Blake Warner6, Torsten Witte7, Roland Jonsson8, Maureen Rischmueller9, Patrick Gaffney1, Judith James1, Lars Ronnblom10, Hal Scofield1, Xavier Mariette11, Marta Alarcon-Riquelme12, Fai Ng13, Gunnel Nordmark10, Qing Sun14, Kwangwoo Kim15, Sang-Cheol Bae16, Betty Tsao14, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Hospitals Birmingham, Birmingham, United Kingdom, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Stavanger University, Stavanger, Norway, 5Karolinska Institutet, Stockholm, Sweden, 6National Institutes of Health, Bethesda, MD, 7MH-Hannover, Hannover, Germany, 8University of Bergen, Bergen, Norway, 9RheumatologySA, Adelaide, Australia, 10Uppsala University, Uppsala, Sweden, 11Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 12Center for Genomics and Oncological Research (GENYO), Granada, Spain, 13Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 14Medical University of South Carolina, Charleston, SC, 15Kyung Hee University, Seoul, Republic of Korea, 16Hanyang University Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Epigenetics, genetics, Sjögren's syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Dysregulated autophagy is implicated in systemic lupus erythematous (SLE) and Sjögren’s disease (SjD), including dysregulated expression of Autophagy-related gene 5 (ATG5) and Autophagy Related 16 Like 2 (ATG16L2) [1-3]. ATG16L2–P2RY2 and PRDM1–ATG5 loci are genome-wide significant (GWS) association in SLE [3,4]. This study aims to identify autophagy-related SLE and SjD risk variants at these loci.

Methods: Bayesian statistics of genome-wide association data (3,762 SLE cases and 6,194 population controls; 3,232 SjD cases and 17,481 population controls) defined a credible SNP set in the PRDM1-ATG5 locus [4,5]. Bioinformatic analyses (RegulomeDB, promoter capture Hi-C, eQTLs, etc.) prioritized SNPs. Luciferase assays tested allele-specific enhancer function in neutrophil-like PLB985 cells and salivary gland A235 cells. PMA/I-induced autophagosome formation was determined by LC3-I to LC3-II conversion and p62 protein aggregation, assessed using Western blotting (WB) and confocal microscopy (CF) in CRISPR/Cas9 knockout (KO) PLB985 cells.

Results: Fine-mapping of PRDM1-ATG5 SLE risk locus identified two SNPs: rs802791 located 11kb 3′ from PRDM1 and rs77791277. SjD association peaked at rs526531, positioned 10kb 3′ of PRDM1.Bioinformatic analyses prioritized rs533733 and rs526531 as eQTLs for ATG5 in minor salivary gland and neutrophils (p< 5×10-2 – 5×10-4). SNP rs533733 showed enrichment of enhancer chromatin marks in monocytes and promoter/TSS marks in neutrophils and is positioned in a topologically associated domain (TAD) 6.4kb 3′ of PRDM1 that engages the ATG5 promoter region where rs9373843 (eQTL of ATG5 in neutrophil) is located.
Luciferase assay in PLB985 and A235 cells showed significant decrease in enhancer activity for rs56885418, rs3804333, rs34599047, rs34582442, and rs533733 (only in A235) risk alleles (p< 5×10-2 – 1×10-4). Interestingly, rs62422881 risk allele showed increased enhancer activity in A235 cells (p = 9×10-4). CRISPR/Cas9 KO of ATG5 or ATG16L1 impaired PMA/I-induced autophagosome formation in myeloid-like and differentiated neutrophil-like PLB985 cells. In contrast, loss of ATG16L2 elevated autophagosome formation, suggesting that ATG16L2 may inhibit autophagy.

Conclusion: ATG5, ATG16L1 are critical regulators of autophagosome formation, and ATG16L2 plays a role as a negative regulator of autophagy in myeloid and neutrophil cell lines. Further, non-protein-coding GWS SNPs carried on the PRDM1-ATG5 risk locus may dysregulate autophagy in SLE and SjD by modulating ATG5 expression through chromatin-chromatin interactions with the ATG5 promoter.

References:
1. Byun YS, et al. Scientific Reports 7.1 (2017): 1-11.
2. Colafrancesco S, et al. Arthritis Research & Therapy 22.1 (2020): 1-8.
3. Lessard CJ, et al. Arthritis Rheumatol. 2016; 68(5):1197-1209.
4. Ye Xin, et al. Frontiers in immunology (2018): 2334.
5. Khatri B, et al. Ann Rheum Dis 2020;79(Suppl1):30.


Disclosures: A. Nagel, None; B. Khatri, None; M. Radziszewski, None; M. Wiley, None; A. Stolarczyk, None; M. Joachims, None; K. Tessneer, None; A. Rasmussen, None; P. Bowman, Novartis, AstraZeneca, AbbVie/Abbott, Galapagos; L. Radfar, None; R. Omdal, None; M. Wahren-Herlenius, None; B. Warner, Pfizer, Astellas Bio; T. Witte, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, UCB, Galapagos; R. Jonsson, None; M. Rischmueller, None; P. Gaffney, None; J. James, Bristol-Myers Squibb(BMS), AstraZeneca, Novartis, Progentec Biosciences; L. Ronnblom, None; H. Scofield, None; X. Mariette, AstraZeneca, Bristol Myers Squibb, Galapagos, GSK, Novartis, Pfizer; M. Alarcon-Riquelme, None; F. Ng, None; G. Nordmark, None; Q. Sun, None; K. Kim, None; S. Bae, None; B. Tsao, None; A. Farris, Janssen; C. Lessard, Janssen.

To cite this abstract in AMA style:

Nagel A, Khatri B, Radziszewski M, Wiley M, Stolarczyk A, Joachims M, Tessneer K, Rasmussen A, Bowman P, Radfar L, Omdal R, Wahren-Herlenius M, Warner B, Witte T, Jonsson R, Rischmueller M, Gaffney P, James J, Ronnblom L, Scofield H, Mariette X, Alarcon-Riquelme M, Ng F, Nordmark G, Sun Q, Kim K, Bae S, Tsao B, Farris A, Lessard C. Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/autophagy-related-risk-loci-in-systemic-lupus-erythematous-and-sjo%cc%88grens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autophagy-related-risk-loci-in-systemic-lupus-erythematous-and-sjo%cc%88grens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology